Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Andlauer Healthcare Group (ANDHF – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report) and Chemomab Therapeutics (CMMB – Research Report).
Andlauer Healthcare Group (ANDHF)
In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Andlauer Healthcare Group, with a price target of C$52.00. The company’s shares closed last Friday at $37.80.
According to TipRanks.com, Keywood is a 2-star analyst with an average return of
Andlauer Healthcare Group has an analyst consensus of Moderate Buy, with a price target consensus of $36.92.
See Insiders’ Hot Stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
Oppenheimer analyst Jay Olson maintained a Hold rating on ACADIA Pharmaceuticals today and set a price target of $19.00. The company’s shares closed last Friday at $17.05, close to its 52-week low of $16.16.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $30.23.
Chemomab Therapeutics (CMMB)
Oppenheimer analyst Jeff Jones upgraded Chemomab Therapeutics to Buy today and set a price target of $6.00. The company’s shares closed last Friday at $0.74.
According to TipRanks.com, Jones is a 5-star analyst with an average return of
Currently, the analyst consensus on Chemomab Therapeutics is a Moderate Buy with an average price target of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANDHF:
